A Twelve-Month, Randomized, Multicenter, Open-Label, Exploratory Study to Investigate the Clinical Outcomes of an Immunosuppressive Regimen of Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Enteric-Coated Mycophenolate Sodium (EC-MPS) Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in De Novo Kidney Recipients Who Are Hepatitis C Positive.

Trial Profile

A Twelve-Month, Randomized, Multicenter, Open-Label, Exploratory Study to Investigate the Clinical Outcomes of an Immunosuppressive Regimen of Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Enteric-Coated Mycophenolate Sodium (EC-MPS) Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in De Novo Kidney Recipients Who Are Hepatitis C Positive.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MYPROMS-ES02
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Additional location (Spain) added as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Planned end date Aug 2006 added as reported by ClinicalTrials.gov.
    • 13 May 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top